Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Allogene Therapeutics, Inc. (ALLO : NSDQ)

• Company Description    Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company, primarily focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer.? Number of Employees: 152

• Price / Volume Information    Yesterday's Closing Price: $1.74 Daily Weekly Monthly 20 Day Moving Average: 9,102,811 shares Shares Outstanding: 345.15 (millions) Market Capitalization: $600.57 (millions) Beta: 0.46 52 Week High: $4.46 52 Week Low: $0.98 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -15.53% -16.15% 12 Week -18.31% -20.55% Year To Date 27.01% 22.75%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 210 EAST GRAND AVENUE - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-457-2700 fax: - ir@allogene.com http://www.allogene.com

• General Corporate Information    Officers David Chang - President; Chief Executive Officer Arie Belldegrun - Executive Chairman Geoffrey Parker - Chief Financial Officer Annie Yoshiyama - Senior Vice President and Corporate Controller Elizabeth Barrett - Director Peer Information Allogene Therapeutics, Inc. (CORR.) Allogene Therapeutics, Inc. (RSPI) Allogene Therapeutics, Inc. (CGXP) Allogene Therapeutics, Inc. (BGEN) Allogene Therapeutics, Inc. (GTBP) Allogene Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 019770106 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/12/26 Share - Related Items Shares Outstanding: 345.15 Most Recent Split Date: (:1) Beta: 0.46 Market Capitalization: $600.57 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.17 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.70 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.53 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 35.71% vs. Previous Quarter: -5.88% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - -56.45 12/31/25 - -57.07 ROA 06/30/26 - - 03/31/26 - -40.36 12/31/25 - -41.63 Current Ratio 06/30/26 - - 03/31/26 - 9.65 12/31/25 - 7.93 Quick Ratio 06/30/26 - - 03/31/26 - 9.65 12/31/25 - 7.93 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - - 03/31/26 - 1.14 12/31/25 - 1.30 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©